BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

Revolutionizing Drug Development: IQVIA's David Cameron on the Power of Innovative Trial Designs

Can you tell us about your role as Senior Director & Global Head of Novel Trial Design at IQVIA? The Novel Trial Design initiative at IQ...

May 09, 2023 | News

The Impact of Digital Health Technologies in Oncology: Current State and Future Directions

Digital health has revolutionized the way healthcare is delivered and managed in recent years. Oncology is one field that has benefited significantly from ...

May 03, 2023 | Opinion

Cellenkos Doses First Patient with CK0803 Cell Therapy for ALS Treatment

Cellenkos® Inc., a clinical stage biotechnology company focused on developing allogeneic, off-the-shelf, T regulatory cell therapies for treatment...

May 03, 2023 | News

New Data Confirms Efficacy of ZIRCON Study in Imaging Kidney Cancer Masses Smaller Than 2cm at AUA

The results were featured in a late-breaking oral presentation delivered on Sunday, 30 April 2023 (CST) by Associate Professor Brian Shuch, ...

May 01, 2023 | News

ALX Oncology collaborates with Sanofi to evaluate Evorpacept with SARCLISA for multiple myeloma

ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 ...

April 28, 2023 | News

RNAimmune's RV-1730 COVID-19 booster vaccine receives FDA clearance for Phase 1 trial.

The proposed clinical study will involve in an evaluation of RV-1730 for its safety and prophylaxis efficacy against SARS-CoV-2 infection with people...

April 28, 2023 | News

I-Mab Doses First Patient in Phase 3 Study of Lemzoparlimab for MDS in China

The Phase 3 trial is a randomized, controlled, open-label, multi-center study to evaluate the efficacy and safety of lemzoparlimab in combination with AZA ...

April 25, 2023 | News

Everest Medicines Launches First-in-Disease Therapy for IgA Nephropathy in China's Hainan Boao Pilot Zone.

The launch of this early-access program in Hainan marks the beginning of a new treatment era for IgA nephropathy in China, where Everest can...

April 24, 2023 | News

Bridge Biotherapeutics Receives FDA Approval for First-in-Human Study of BBT-207, a 4th Gen EGFR TKI.

The company has been notified by the FDA that the Phase 1/2 clinical trial may proceed The latest preclinical data explored the antitumor effica...

April 24, 2023 | News

LTS acquires Sorrel for large molecule drug delivery

LTS LOHMANN Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such a...

April 21, 2023 | News

Lambda Therapeutics partners with Medidata to streamline clinical trial data management

Medidata, a Dassault Systèmes company, announced that Lambda Therapeutics is implementing Medidata's cloud-based clinical solutions – Rave EDC...

April 20, 2023 | News

Agilis Robotics tests animal trial for GI indication, aims 510(k) clearance by 2025 for improved endoscopic surgery.

The system by Agilis Robotics offers a novel combination of features that set it apart from conventional surgical robotic systems. With a remarkably compac...

April 19, 2023 | News

Anixa Biosciences and Cleveland Clinic Present Positive Data for Phase 1 Study of Breast Cancer Vaccine

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer announced that Clev...

April 18, 2023 | News

HUTCHMED's Fruquintinib NDA Accepted in China for 2nd-Line Gastric Cancer

Dr. Michael Shi, Head of R&D and Chief Medical Officer of HUTCHMED said, “The NMPA acceptance of our NDA for fruquintinib is a positive step towa...

April 18, 2023 | News

Stay Connected